Clinical Medicine Frontiers is an international, peer-reviewed open access journal dedicated to advancing research the field of clinical medicine. The journal provides a rapid publication process to ensure wide dissemination of high-quality articles to scientists, professionals, and interested individuals worldwide. Our goal is to serve as an efficient, reliable, and trusted platform for scholars and readers, publishing cutting-edge research in the field.
Abstract: Purpose Aimed to comprehensively investigate the efficacy and safety of the dual GIP/GLP-1 re-ceptor agonist Tirzepatide on overweight and obesity. Methods Embase, PubMed/Medline, Web of Science, Cochrane, CNKI, Wanfang and VIP databases were searched using standard key-words to identify all controlled trials investigating the weight loss effects of Tirzepatide. RevMan 5.3 was used for analysis. Results Eleven randomized controlled trials with 11710 participants were included in this systematic review and meta-regression analysis. The pooled findings showed that Tirzepatide vs control significantly reduced body weight (mean difference (MD): -7.38, 95% confidence interval (CI): -13.66 to -1.09, P=0.02). The results of subgroup analysis showed that the trend of weight loss is dose-dependent (5mg: MD: -6.87, 95%CI: -10.29 to -3.45, P<0.0001; 10 mg: MD: -9.62, 95%CI: -13.11 to -6.13, P<0.000 01; 15mg: MD: -11.00, 95%CI: -14.29 to -7.70, P<0.000 01). HbA1c (MD: -1.38, 95% CI: -1.52 to -1.23, P<0.000 01). The total incidence of adverse reactions in Tirzepatide vs control was significantly increased (Odds Ratio (OR): 1.57, 95%CI: 1.35 to 1.81, P<0.000 01), and these adverse reactions were even greater, especially with higher doses and duration of Tirzepatide. Conclusions The administration of Tirzepatide medication has demonstrated noteworthy effects on weight management, resulting in reductions in both body weight and HbA1c levels. These effects may potentially be dependent on the dosage administered. Consequently, for individuals with diabetes who experience significant impacts on body weight, the utilization of Tirzepatide can be regarded as a viable therapeutic approach for obese individuals.Abstract: Purpose Aimed to comprehensively investigate the efficacy and safety of the dual GIP/GLP-1 re-ceptor agonist Tirzepatide on overweight and obesity. Methods Embase, PubMed/Medline, Web of Science, Cochrane, CNKI, Wanfang and VIP databases were searched using standard key-words to identify all controlled trials investigating the weight loss effects o...Learn More
Abstract: Medical History Abstract: Patient, male, 32 years old, presented to our expert outpatient clinic on October 15, 2023, due to “progressive right-leg gait after more than a year of taking antipsychotic medication.” The patient had previously visited numerous large hospitals in Guangxi and other provinces, but there had been no improvement. Examination of the muscles and nervous system at a prominent Beijing comprehensive hospital revealed no abnormalities. The patient returned to our expert outpatient clinic on March 17, 2025. Symptoms and findings: Conscious and oriented, normal contact, no signs of mental symptoms. No significant abnormalities in the nervous system. Muscles below the knee in the right leg were stiff, with increased muscle tone, preventing straightening. This resulted in a gait resembling a stride-and-pause pattern. Diagnosis: The patient developed movement disorders six months after starting antipsychotic medication (risperidone). A comprehensive examination at a Beijing hospital ruled out muscle and nervous system disorders. The diagnosis was consistent with tardive dyskinesia, characterized by the onset of movement disorders six months or more after initiating antipsychotic treatment. Treatment Plan: Based on the patient’s medical history and diagnosis, the most effective treatment for tardive dyskinesia currently available is deutetrabenazine tablets. Starting with a low dose and gradually increasing the dosage over time was recommended, taking into account the patient’s medication regimen and overall health. Clinical Outcome: After four weeks of treatment, the patient’s muscle tone in the right leg returned to normal, and he was able to walk normally again. Follow-up one month later showed that the condition remained stable. The patient continues to receive treatment.Abstract: Medical History Abstract: Patient, male, 32 years old, presented to our expert outpatient clinic on October 15, 2023, due to “progressive right-leg gait after more than a year of taking antipsychotic medication.” The patient had previously visited numerous large hospitals in Guangxi and other provinces, but there had been no improvement. Examinatio...Learn More
